Publication Date

2011

Abstract

Background: Mineralocorticoid antagonists improve survival among patients with chronic, severe systolic heart failure and heart failure after myocardial infarction. We evaluated the effects of eplerenone in patients with chronic systolic heart failure and mild symptoms. Methods: In this randomized, double-blind trial, we randomly assigned 2737 patients with New York Heart Association class II heart failure and an ejection fraction of no more than 35% to receive eplerenone ( up to 50 mg daily ) or placebo, in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure. Results: The trial was stopped prematurely, according to prespecified rules, after a median follow-up period of 21 months. The primary outcome occurred in 18.3% of patients in the eplerenone group as compared with 25.9% in the placebo group ( hazard ratio, 0.63; 95% confidence interval [CI], 0.54 to 0.74; P < 0.001 ). A total of 12.5% of patients receiving eplerenone and 15.5% of those receiving placebo died ( hazard ratio, 0.76; 95% CI, 0.62 to 0.93; P=0.008 ); 10.8% and 13.5%, respectively, died of cardiovascular causes ( hazard ratio, 0.76; 95% CI, 0.61 to 0.94; P=0.01 ). Hospitalizations for heart failure and for any cause were also reduced with eplerenone. A serum potassium level exceeding 5.5 mmol per liter occurred in 11.8% of patients in the eplerenone group and 7.2% of those in the placebo group ( P < 0.001 ). Conclusions: Eplerenone, as compared with placebo, reduced both the risk of death and the risk of hospitalization among patients with systolic heart failure and mild symptoms. ( Funded by Pfizer; ClinicalTrials.gov number, NCT00232180. )

School/Institute

Mary MacKillop Institute for Health Research

Document Type

Journal Article

Access Rights

ERA Access

Access may be restricted.

Share

COinS